BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 27050150)

  • 1. The tumor-inhibitory effectiveness of a novel anti-Trop2 Fab conjugate in pancreatic cancer.
    Mao Y; Wang X; Zheng F; Wang C; Tang Q; Tang X; Xu N; Zhang H; Zhang D; Xiong L; Liang J; Zhu J
    Oncotarget; 2016 Apr; 7(17):24810-23. PubMed ID: 27050150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel human Fab antibody for Trop2 inhibits breast cancer growth in vitro and in vivo.
    Lin H; Zhang H; Wang J; Lu M; Zheng F; Wang C; Tang X; Xu N; Chen R; Zhang D; Zhao P; Zhu J; Mao Y; Feng Z
    Int J Cancer; 2014 Mar; 134(5):1239-49. PubMed ID: 23982827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Photoimmunotherapy targeting biliary-pancreatic cancer with humanized anti-TROP2 antibody.
    Nishimura T; Mitsunaga M; Sawada R; Saruta M; Kobayashi H; Matsumoto N; Kanke T; Yanai H; Nakamura K
    Cancer Med; 2019 Dec; 8(18):7781-7792. PubMed ID: 31674732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel human monoclonal Trop2-IgG antibody inhibits ovarian cancer growth in vitro and in vivo.
    Liu J; Yang D; Yin Z; Gao M; Tong H; Su Y; Zhu J; Ye C; Zhang H
    Biochem Biophys Res Commun; 2019 Apr; 512(2):276-282. PubMed ID: 30879767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma.
    Moldenhauer G; Salnikov AV; Lüttgau S; Herr I; Anderl J; Faulstich H
    J Natl Cancer Inst; 2012 Apr; 104(8):622-34. PubMed ID: 22457476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. hIMB1636-MMAE, a Novel TROP2-Targeting Antibody-Drug Conjugate Exerting Potent Antitumor Efficacy in Pancreatic Cancer.
    Sun LP; Bai WQ; Zhou DD; Wu XF; Zhang LW; Cui AL; Xie ZH; Gao RJ; Zhen YS; Li ZR; Miao QF
    J Med Chem; 2023 Nov; 66(21):14700-14715. PubMed ID: 37883180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-Trop2 antibody-conjugated bioreducible nanoparticles for targeted triple negative breast cancer therapy.
    Son S; Shin S; Rao NV; Um W; Jeon J; Ko H; Deepagan VG; Kwon S; Lee JY; Park JH
    Int J Biol Macromol; 2018 Apr; 110():406-415. PubMed ID: 29055700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma.
    Han C; Perrone E; Zeybek B; Bellone S; Tymon-Rosario J; Altwerger G; Menderes G; Feinberg J; Haines K; Muller Karger ME; Bianchi A; Zammataro L; Manzano A; Bonazzoli E; Manara P; Buza N; Hui P; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Lopez S; Santin AD
    Gynecol Oncol; 2020 Feb; 156(2):430-438. PubMed ID: 31839338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor effect of antitissue factor antibody-MMAE conjugate in human pancreatic tumor xenografts.
    Koga Y; Manabe S; Aihara Y; Sato R; Tsumura R; Iwafuji H; Furuya F; Fuchigami H; Fujiwara Y; Hisada Y; Yamamoto Y; Yasunaga M; Matsumura Y
    Int J Cancer; 2015 Sep; 137(6):1457-66. PubMed ID: 25704403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-Sp17 monoclonal antibody-doxorubicin conjugates as molecularly targeted chemotherapy for ovarian carcinoma.
    Song JX; Li FQ; Cao WL; Jia X; Shi LN; Lu JF; Ma CF; Kong QQ
    Target Oncol; 2014 Sep; 9(3):263-72. PubMed ID: 23943313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells.
    Okajima D; Yasuda S; Maejima T; Karibe T; Sakurai K; Aida T; Toki T; Yamaguchi J; Kitamura M; Kamei R; Fujitani T; Honda T; Shibutani T; Muramatsu S; Nakada T; Goto R; Takahashi S; Yamaguchi M; Hamada H; Noguchi Y; Murakami M; Abe Y; Agatsuma T
    Mol Cancer Ther; 2021 Dec; 20(12):2329-2340. PubMed ID: 34413126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer.
    Xu C; Zhu M; Wang Q; Cui J; Huang Y; Huang X; Huang J; Gai J; Li G; Qiao P; Zeng X; Ju D; Wan Y; Zhang X
    J Nanobiotechnology; 2023 Nov; 21(1):410. PubMed ID: 37932752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-associated calcium signal transducer 2 regulates neovascularization of non-small-cell lung cancer via activating ERK1/2 signaling pathway.
    Guo X; Zhu X; Zhao L; Li X; Cheng D; Feng K
    Tumour Biol; 2017 Mar; 39(3):1010428317694324. PubMed ID: 28345466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates.
    Trail PA; Willner D; Knipe J; Henderson AJ; Lasch SJ; Zoeckler ME; TrailSmith MD; Doyle TW; King HD; Casazza AM; Braslawsky GR; Brown J; Hofstead SJ; Greenfield RS; Firestone RA; Mosure K; Kadow KF; Yang MB; Hellström KE; Hellström I
    Cancer Res; 1997 Jan; 57(1):100-5. PubMed ID: 8988048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models.
    Challita-Eid PM; Satpayev D; Yang P; An Z; Morrison K; Shostak Y; Raitano A; Nadell R; Liu W; Lortie DR; Capo L; Verlinsky A; Leavitt M; Malik F; Aviña H; Guevara CI; Dinh N; Karki S; Anand BS; Pereira DS; Joseph IB; Doñate F; Morrison K; Stover DR
    Cancer Res; 2016 May; 76(10):3003-13. PubMed ID: 27013195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antigen-specific activity of carcinoma-reactive BR64-doxorubicin conjugates evaluated in vitro and in human tumor xenograft models.
    Trail PA; Willner D; Lasch SJ; Henderson AJ; Greenfield RS; King D; Zoeckler ME; Braslawsky GR
    Cancer Res; 1992 Oct; 52(20):5693-700. PubMed ID: 1382845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Antibody-Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies.
    Asundi J; Crocker L; Tremayne J; Chang P; Sakanaka C; Tanguay J; Spencer S; Chalasani S; Luis E; Gascoigne K; Desai R; Raja R; Friedman BA; Haverty PM; Polakis P; Firestein R
    Clin Cancer Res; 2015 Jul; 21(14):3252-62. PubMed ID: 25862760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Trop2 in solid tumors: a look into structures and novel epitopes.
    Liu X; Li J; Deng J; Zhao J; Zhao G; Zhang T; Jiang H; Liang B; Xing D; Wang J
    Front Immunol; 2023; 14():1332489. PubMed ID: 38179054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific Conjugation of the Hinge Region for Homogeneous Preparation of Antibody Fragment-Drug Conjugate: A Case Study for Doxorubicin-PEG-anti-CD20 Fab' Synthesis.
    Zhou Z; Zhang J; Zhang Y; Ma G; Su Z
    Bioconjug Chem; 2016 Jan; 27(1):238-46. PubMed ID: 26700095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway.
    Cubas R; Zhang S; Li M; Chen C; Yao Q
    Mol Cancer; 2010 Sep; 9():253. PubMed ID: 20858281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.